Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
Figlin
R A
RA
Department of Medicine, Jonsson Comprehensive Cancer Center, UCLA School of Medicine 90024.
Pierce
W C
WC
Belldegrun
A
A
D000553:Ambulatory Care; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000502:physiology; D007376:Interleukin-2 / Q000008:administration & dosage / Q000502:physiology / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy*; D015979:Killer Cells, Lymphokine-Activated; D016246:Lymphocytes, Tumor-Infiltrating; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
D007370:Interferon Type I; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins